Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bushi Wang

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|February 17, 2016
Sample size determination with familywise control of both type I and type II errors in clinical trialsBushi Wang, Naitee Ting
Biometrical Journal. Biometrische Zeitschrift|April 25, 2017
An improved uniformly more powerful exact Fisher-Hayter pairwise comparisons procedureBushi Wang, Xinping Cui
Statistics in Medicine|August 27, 2010
Consonant closed likelihood ratio test procedures with application to dose-response studyBushi Wang, Xinping Cui
Statistics in Medicine|April 26, 2012
A new partition testing strategy for multiple endpointsBushi Wang, Xinping Cui
Frontiers in Public Health|January 17, 2014
An Application of Graphical Approach to Construct Multiple Testing Procedures in a Hypothetical Phase III DesignBushi Wang, Naitee Ting
Biometrical Journal. Biometrische Zeitschrift|July 29, 2010
General solutions to consistency problems in multiple hypothesis testingHaibing Zhao, Bushi Wang, Xinping Cui
Biometrical Journal. Biometrische Zeitschrift|July 16, 2021
Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trialsYi Liu, Bushi Wang, Hong Tian, et al.
Biometrical Journal. Biometrische Zeitschrift|February 13, 2022
Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trialsYi Liu, Bushi Wang, Miao Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.
Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|February 17, 2016
Sample size determination with familywise control of both type I and type II errors in clinical trialsBushi Wang, Naitee Ting
Biometrical Journal. Biometrische Zeitschrift|April 25, 2017
An improved uniformly more powerful exact Fisher-Hayter pairwise comparisons procedureBushi Wang, Xinping Cui
Statistics in Medicine|August 27, 2010
Consonant closed likelihood ratio test procedures with application to dose-response studyBushi Wang, Xinping Cui
Statistics in Medicine|April 26, 2012
A new partition testing strategy for multiple endpointsBushi Wang, Xinping Cui
Frontiers in Public Health|January 17, 2014
An Application of Graphical Approach to Construct Multiple Testing Procedures in a Hypothetical Phase III DesignBushi Wang, Naitee Ting
Biometrical Journal. Biometrische Zeitschrift|July 29, 2010
General solutions to consistency problems in multiple hypothesis testingHaibing Zhao, Bushi Wang, Xinping Cui
Biometrical Journal. Biometrische Zeitschrift|July 16, 2021
Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trialsYi Liu, Bushi Wang, Hong Tian, et al.
Biometrical Journal. Biometrische Zeitschrift|February 13, 2022
Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trialsYi Liu, Bushi Wang, Miao Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.
Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Pageof 2